Skip to main content
SpringerLink
Log in

Risks and Benefits of Aromatase Inhibitors in Postmenopausal Breast Cancer

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Aromatase inhibitors were first reported in the early 1970s and have been used to treat breast cancer since that time. Until recently, essentially the only agent available in this class was aminoglutethimide, a nonspecific inhibitor with multiple adverse effects and drug interactions. Selective and potent aromatase inhibitors are now available (formestane, exemestane, fadrozole, anastrozole and letrozole), and we review the risks and benefits of these agents in order to assist clinicians in making treatment decisions.

Formestane is an injectable steroidal aromatase inhibitor with significant activity against metastatic breast cancer. It has been shown to have similar efficacy and superior tolerability compared with megestrol, and is similar to tamoxifen in the metastatic setting. Exemestane is an oral steroidal aromatase inhibitor. It has been shown to be effective third-line therapy after tamoxifen and megestrol in post-menopausal patients with metastatic breast cancer. All the nonsteroidal (imidazole/triazole) aromatase inhibitors are orally available. Fadrozole has similar activity to megestrol and tamoxifen in the setting of metastasis, but has been shown in phase II trials to inhibit cortisol and aldosterone production. Anastrozole and letrozole have similar toxicity profiles. Compared with megestrol, anastrozole improves overall survival and has superior tolerability. Letrozole is superior to megestrol and aminoglutethimide in terms of overall survival and time to progression, and is also better tolerated.

Although there is a strong rationale for using these agents in the treatment of breast cancer, the information presently available is insufficient to recommend any one agent over another. Direct comparative studies are lacking, and comparing agents across studies is limited by many biases and may not be valid. Formestane is only available as an injection and exemestane is not commercially available in many countries, making these agents more difficult to recommend over the other 3 agents. Fadrozole is less potent and less selective in inhibiting aromatase than letrozole. The efficacies of fadrozole, megestrol and tamoxifen appear to be similar; however, comparative data show no advantage of fadrozole over letrozole. Anastrozole and letrozole are generally considered to be similar agents.

The clinical future of the selective aromatase inhibitors is promising, and these agents may change the way postmenopausal breast cancer is treated at all stages of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Brodie A, Lu Q, Liu Y, et al. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer. Oncology 1998; 12(3): 36–40

    PubMed  CAS  Google Scholar 

  2. Santen RJ, Worgul TJ, Lipton A, et al. Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. Ann Intern Med 1982; 96: 94–101

    PubMed  CAS  Google Scholar 

  3. Hansten PD, Horn JR, editors. Drug interactions and updates. Vancouver, Washington: Applied Therapeutics, Inc, 1997

    Google Scholar 

  4. Brodie A, Hendrickson J, Tsai-Morris C. Inactivation of aromatase in vitro by 4-OHA and 4-acetoxyandrostenedione and sustained effects in vivo. Steroids 1981; 38: 696–702

    Article  Google Scholar 

  5. Dowsett M, Coombes RC. Second generation aromatase inhibitor — 4-hydroxyandrostenedione. Breast Cancer Res Treat 1994; 30: 81–7

    Article  PubMed  CAS  Google Scholar 

  6. Di Salle E, Ornati G, Giudici D, et al. Exemestane (FCE 24304), a new steroidal aromatase inhibitor. J Steroid Biochem Mol Biol 1992; 43(1–3): 137–43

    Article  PubMed  Google Scholar 

  7. Brodie A, Njar V. Aromatase inhibitors and breast cancer. Semin Oncol 1996; 23: 10–20

    PubMed  CAS  Google Scholar 

  8. Demers LM. Effects of fadrozole (CGS16949A) and letrozole (CGS20267) on the inhibition of aromatase activity in breast cancer patients. Breast Cancer Res Treat 1994; 30(1): 95–102

    Article  PubMed  CAS  Google Scholar 

  9. Arimidex® (anastrozole) product information. Wilmington (DE): Zeneca Pharmaceuticals, Jan 1997

  10. Femara® (letrozole) product information. East Hanover (NJ): Novartis Pharmaceutical Corporation, Jul 1997

  11. Dowsett M, Pfister CU, Johnston SRD, et al. Pharmacokinetic interaction between letrozole and tamoxifen in postmenopausal patients with advanced breast cancer [abstract]. Breast 1997; 6: 245

    Google Scholar 

  12. Dowsett M, Welch H, Blackman GM, et al. A randomised, double blind, parallel-group trial to evaluate the effect of ‘Arimidex’ (anastrozole) on the pharmacokinetics of tamoxifen in postmenopausal breast cancer patients [abstract no. 103]. Breast Cancer Res Treat 1997; 46: 28

    Google Scholar 

  13. Tominaga T, Yoshida Y, Shimozuma K, et al. Effect of CGS 16949 A plus tamoxifen on induced mammary tumours in rats. Eur J Cancer 1990; 26: 600–3

    Article  PubMed  CAS  Google Scholar 

  14. Zaccheo T, Giudici D, Di Salle E. Inhibitory effect of combined treatment with the aromatase inhibitor exemestane and tamoxifen on DMBA-induced mammary tumors in rats. J Steroid Biochem Mol Biol 1993; 44: 677–80

    Article  PubMed  CAS  Google Scholar 

  15. Dowsett M. Aromatase inhibition: basic concepts, and the pharmacodynamics of formestane. Ann Oncol 1994; 5 Suppl. 7: S3–S5

    PubMed  Google Scholar 

  16. Plourde PV, Dyroff M, Dukes M. Arimidex®: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat 1994; 30: 103–11

    Article  PubMed  CAS  Google Scholar 

  17. Sioufi A, Gauducheau N, Pineau V, et al. Absolute bioavailability of letrozole in healthy postmenopausal women. Biopharm Drug Dispos 1997; 18(9): 779–89

    Article  PubMed  CAS  Google Scholar 

  18. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997 Nov 19; 89(22): 1673–82

    Article  PubMed  CAS  Google Scholar 

  19. Perez Carrion R, Alberola Candel V, Calabresi F, et al. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol 1994; 5 Suppl. 7: S19–24

    PubMed  Google Scholar 

  20. Zilembo N, Noberasco C, Bajetta E, et al. Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. Br J Cancer 1995; 72: 1007–12

    Article  PubMed  CAS  Google Scholar 

  21. Evans T, Di Salle E, Ornati G, et al. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res 1992; 52: 5933–9

    PubMed  CAS  Google Scholar 

  22. Buzdar AU, Smith R, Vogel C, et al. Fadrozole HCl (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multi-institutional trials. Cancer 1996 Jun 15; 77(12): 2503–13

    Article  PubMed  CAS  Google Scholar 

  23. Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 1996 Jul; 14(7): 2000–11

    PubMed  CAS  Google Scholar 

  24. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: doubleblind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16(2): 453–61

    PubMed  CAS  Google Scholar 

  25. Goss PE, Powles TJ, Dowsett M, et al. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report. Cancer Res 1986; 46: 4823–6

    PubMed  CAS  Google Scholar 

  26. Stein RC, Dowsett M, Hedley A, et al. Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione. Cancer Chemother Pharmacol 1990; 26(1): 75–8

    Article  PubMed  CAS  Google Scholar 

  27. Rose C, Freue M, Kjaer M, et al. An open, comparative randomized trial comparing formestane vs oral megestrol acetate as second-line therapy in postmenopausal advanced breast cancer patients [abstract no. PP-8-4]. Eur J Cancer 1996; 32A Suppl. 2: 49

    Article  Google Scholar 

  28. Dowsett M, Cunningham D, Stein R, et al. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res 1989; 49: 1306–12

    PubMed  CAS  Google Scholar 

  29. Kvinnsland S, Anker G, Dirix LY, et al. Antitumor efficacy of exemestane, a novel, irreversible, oral, aromatase inhibitor in postmenopausal patients with metastatic breast cancer (MBC), failing tamoxifen (TAM) [abstract no. 217]. Breast Cancer Res Treat 1997 Dec; 46: 55

    Google Scholar 

  30. Thurlimann B, Beretta K, Bacchi M, et al. First-line fadrozole HCl (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer: prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Ann Oncol 1996: 7(5): 471–9

    Article  PubMed  CAS  Google Scholar 

  31. Falkson CI, Falkson HC. A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer. Ann Oncol 1996 Jul; 7(5): 433–7

    Article  Google Scholar 

  32. Dowsett M, Vorobiof D, Kleeberg U, et al. A randomized comparison assessing oestrogen suppression with Arimidex® (anastrozole) and formestane in postmenopausal advanced breast cancer patients [abstract]. Eur J Cancer 1996; 32A Suppl. 2: 49–50

    Article  Google Scholar 

  33. Marty M, Gershanovich M, Campos B, et al. Letrozole, a new potent, selective aromatase inhibitor (AI) superior to aminoglutethimide (AG) in postmenopausal women with advanced breast cancer (ABC) previously treated with antiestrogens [abstract no. 544]. Proc Am Soc Clin Oncol 1997; 16: 156a

    Google Scholar 

  34. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996; 88(21): 1529–42

    Article  PubMed  CAS  Google Scholar 

  35. Lonning PE. Aromatase inhibition for breast cancer treatment. Acta Oncol 1996; 35 Suppl. 5: 38–43

    Article  PubMed  Google Scholar 

  36. Klein KO, Demers LM, Santner SJ, et al. Use of ultrasensitive recombinant cell bioassay to measure estrogen levels in women with breast cancer receiving the aromatase inhibitor, letrozole. J Clin Endocrinol Metab 1995; 80: 2658–60

    Article  PubMed  CAS  Google Scholar 

  37. Jacobs SL, Lonning PE, Haynes B, et al. Measurement of aromatization by a urine technique suitable for the evaluation of inhibitors in vivo. J Enzyme Inhib 1991; 4: 315–25

    Article  PubMed  CAS  Google Scholar 

  38. Jones AL, MacNeill F, Jacobs S, et al. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatization in breast cancer patients. Eur J Cancer 1992; 28: 1712–6

    Article  Google Scholar 

  39. Dowsett M, Jones A, Johnston SRD, et al. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1995; 1: 1511–5

    PubMed  CAS  Google Scholar 

  40. Geisler J, King N, Dowsett M, et al. Influence of anastrozole (Arimidex), a selective nonsteroidal aromatase inhibitor, on in vivo aromatase and plasma oestrogen levels in post-menopausal women with breast cancer. Br J Cancer 1996; 74: 1286–91

    Article  PubMed  CAS  Google Scholar 

  41. Noberasco C, Bajetta E, Zilembo N, et al. Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer. Oncology 1995; 52: 454–7

    Article  PubMed  CAS  Google Scholar 

  42. Murray R, Pitt P. Aromatase inhibition with 4-OH-androstenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res Treat 1995; 35: 249–53

    Article  PubMed  CAS  Google Scholar 

  43. Jones S, Vogel C, Fehrenbacher L, et al. Antitumor efficacy of exemestane (Nikidess®, EXE) as third-line hormonal therapy in the treatment of postmenopausal women with metastatic breast cancer refractory to tamoxifen and Megace® [abstract no. 573]. Proc Am Soc Clin Oncol 1998; 17: 150a

    Google Scholar 

  44. Howell A, Buzdar A, Jonat W, et al. Significantly improved survival with ‘Arimidex’ (anastrozole) (AN) compared with megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC): updated results of two randomised trials [abstract no. 18]. Breast Cancer Res Treat 1997; 46: 27

    Google Scholar 

  45. Smith IE, Chaudri HA, Lassus M, et al. Comparison of overall survival (OS) in two trials comparing letrozole 2.5mg (Femara) with megestrol acetate (MA) or aminoglutethimide (AG) in patients with advanced breast cancer (ABC) [abstract no. 19]. Breast Cancer Res Treat 1997; 46: 27

    Google Scholar 

  46. Michaud LB, Knoche AJ, Abbott B, et al. Efficacy of anastrozole (Arimidex®) in a consecutive series of advanced breast cancer patients: M.D. Anderson Cancer Center (MDACC) experience [abstract no. 641]. Proc Am Soc Clin Oncol 1997; 16: 183a

    Google Scholar 

  47. Manni A, Arafah BU, Pearson OH. Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy. Cancer 1980; 46(12 Suppl.): 2838

    Article  PubMed  CAS  Google Scholar 

  48. Bolufer P, Ricart E, Lluch A, et al. Aromatase activity and oestradiol in human breast cancer: its relationship to oestradiol and epidermal growth factor. J Clin Oncol 1992; 10: 438–46

    PubMed  CAS  Google Scholar 

  49. Gershanovich M, Chaudri HA, Hornberger U, et al. Comparison of letrozole 2.5mg (Femara®) with megestrol acetate (MA) and with aminoglutethimide (AG) in patients with visceral disease (abstract no. 212). Breast Cancer Res Treat 1997; 46: 53

    Google Scholar 

  50. Howell A, Mackintosh J, Jones M, et al. The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol 1988; 24: 1567–72

    Article  PubMed  CAS  Google Scholar 

  51. Robertson JFR, Williams MR, Todd J, et al. Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur J Cancer Clin Oncol 1989; 23: 469–75

    Article  Google Scholar 

  52. Kelloff GJ, Lubet RA, Lieberman R, et al. Aromatase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 1998; 7: 65–78

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pharmacy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

    Laura Boehnke Michaud

  2. Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 56, Houston, Texas, TX 77030, USA

    Aman U. Buzdar

Authors
  1. Laura Boehnke Michaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aman U. Buzdar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aman U. Buzdar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Michaud, L.B., Buzdar, A.U. Risks and Benefits of Aromatase Inhibitors in Postmenopausal Breast Cancer. Drug-Safety 21, 297–309 (1999). https://doi.org/10.2165/00002018-199921040-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199921040-00005

Keywords

Search

Navigation